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Streptococcus pneumoniae (S. pneumoniae)
causes high early mortality in pneumococcal
pneumonia, which is characterized by acute
lung injury (ALI). Themolecularmechanisms un-
derlying ALI and the high early mortality remain
unknown. Despite recent studies that identify
deubiquitinating enzyme cylindromatosis (CYLD)
as a key regulator for T cell development, tumor
cell proliferation, andNF-kB transcription factor
signaling, its role in regulating bacteria-induced
lethality, however, is unknown. Here, we showed
that CYLD deficiency protected mice from S.
pneumoniae pneumolysin (PLY)-induced ALI
and lethality. CYLD was highly induced by
PLY, and it inhibited MKK3-p38 kinase-depen-
dent expression of plasminogen activator in-
hibitor-1 (PAI-1) in lung, thereby potentiating
ALI and mortality. Thus, CYLD is detrimental
for host survival, thereby indicating a mecha-
nismunderlying the high earlymortality of pneu-
mococcal pneumonia.
INTRODUCTION
Streptococcus pneumoniae (S. pneumoniae) is a major
cause of morbidity and mortality worldwide. Despite the
widespread use of antibiotics, the mortality rate fromsevere S. pneumoniae pneumonia remains highest during
the first 48 hr of hospitalization and has not decreased ap-
preciably over the past 30 years (Brandenburg et al., 2000;
Hollingshed and Briles, 2001). The earliest stage, which
causes antibiotics nonresponsive higher mortality, is sel-
dom recognized and is most likely to be found in patients
who die after illness lasting only a short time period be-
cause of the very rapid progress of the disease in some
of the infected individuals (Loeschcke, 1931). The molec-
ular mechanism underlying the high early mortality, how-
ever, remains unknown (Grigoryev et al., 2004; Kadioglu
and Andrew, 2004). Histologically, the initial phase of
pneumococcal pneumonia is characterized by acute
lung injury (ALI). Although numerous bacteria are present
in an actively spreading lesion, few inflammatory cells
are seen in this serous exudates because leukocytes
have not had time to reach the alveoli in the advancing
edema zone, suggesting that alveolar epithelial cell injury
may be caused directly by pneumococcal toxins rather
than by leukocytes themselves or their products (Hasle-
ton, 1996; Tuomanen et al., 1995; Wood, 1941). Among
a variety of virulence factors that have been identified,
pneumolysin (PLY), a 53 kDa protein produced by virtually
all clinical isolates of the S. pneumoniae, plays an impor-
tant role in mortality associated with S. pneumoniae infec-
tions (Cockeran et al., 2002). Moreover, histopathological
change of pneumococcal pneumonia was reproduced
with PLY in vivo (Maus et al., 2004). Electron microscopy
revealed that instilled PLY caused widespread lung injury.
Direct cytotoxic effect of PLY to the alveolar epithelium,
as well as to the pulmonary endothelium, may produceImmunity 27, 349–360, August 2007 ª2007 Elsevier Inc. 349
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Regulation of S. pneumoniae Infections by CYLDFigure 1. S. pneumoniae Pneumolysin Induces ALI and Lethality In Vivo
(A). Survival curves of WT mice after i.t. inoculation of saline (CON), live S. pneumoniae, and S. pneumoniae lysate. *p < 0.0005 compared with CON;
**p < 0.0005 compared with live S. pneumoniae.
(B) Survival curves of WT mice after i.t. inoculation of S. pneumoniae WT or Ply MT lysate or purified PLY. *p < 0.0005 compared with CON; **p <
0.0005 compared with S. pneumoniae WT lysate.
(C) Representative pathological and histological analysis of the lungs of mice inoculated with S. pneumoniaeWT and Ply MT lysate and PLY 6 hr after
inoculation (Lower panel: H&E, 3100).
Viability in (A) and (B) was assessed by using Kaplan-Meier survival analysis and compared by log-lank test (n = 10 to 44).alveolar flooding and hemorrhage during the earliest
stages of pneumococcal pneumonia. The resulting serous
exudatesmay in turn promote the rapidmultiplication of S.
pneumoniaewithin thealveoli. The lesionprogresses to the
state known as red hepatization, which results from leak-
age of erythrocytes into the alveoli (Rubins et al., 1993).
The deubiquitinating enzyme cylindromatosis (CYLD)
was initially identified as a tumor suppressor because
loss of which causes a benign human tumor called cylin-
dromatosis. CYLD has also been identified as a key neg-
ative regulator for NF-kB signaling, T cell development,
and tumor cell proliferation (Brummelkamp et al., 2003;
Kovalenko et al., 2003; Massoumi et al., 2006; Reiley
et al., 2006; Trompouki et al., 2003; Yoshida et al.,
2005). We have shown that CYLD is induced by Gram-
negative and Gram-positive bacterial pathogens (Jono
et al., 2004; Yoshida et al., 2005). However, the biological
role of CYLD in bacteria infection in vivo remains un-
known. Its role in regulation of bacterial toxin-induced
lung injury and lethality also remains unclear.
In the present study, we showed that CYLD deficiency
protected mice from S. pneumoniae PLY-induced ALI,
bacterial translocation, and lethality, and thus acted detri-
mental for host survival during early S. pneumoniae infec-
tions. We demonstrated that CYLD, highly induced by
PLY, negatively regulated MKK3-p38 kinase-dependent
expression of plasminogen activator inhibitor-1 (PAI-1) in
lung, which in turn led to potentiation of lung injury and
increased mortality. Our studies thus unveiled a mecha-
nism underlying the high early mortality of S. pneumoniae
infections and may lead to development of therapeutic
strategies for reducing high early mortality in lethal
S. pneumoniae infections.350 Immunity 27, 349–360, August 2007 ª2007 Elsevier Inc.RESULTS
S. pneumoniae Pneumolysin Induces ALI
and Lethality In Vivo
To investigate the molecular mechanism underlying S.
pneumoniae-induced ALI and lethality in severe pneumo-
coccal pneumonia, lethal pneumonia was first induced in
wild-type (WT) mice by intratracheal (i.t.) inoculation of
liveS. pneumoniae (a virulent serotype 2D39).S. pneumo-
niae undergoes spontaneous autolysis, and autolysis can
also be triggered in vivo under various conditions includ-
ing antibiotic treatment. PLY, a cytoplasmic protein re-
leased from lysed bacteria, is known to exert potent cyto-
toxic effects on host cells to cause tissue damage such as
ALI (Cockeran et al., 2002; Hollingshed and Briles, 2001).
Therefore, we evaluated the effect of i.t. inoculation of S.
pneumoniae lysate in WT mice. Live S. pneumoniae-inoc-
ulatedmice started to die within 48 hr after inoculation and
nearly 66% of the inoculated mice died within 72 hr
(Figure 1A). In contrast, mice inoculated with S. pneumo-
niaeWT lysate started to die within a few hours after inoc-
ulation and 91% of the inoculated mice died within 48 hr,
implying an important role for released virulence factors
such as PLY in inducing lethality.
To further determine if PLY plays a key role in S. pneu-
moniae-induced lethality, we compared the lethality in
mice inoculated with PLY-deficient mutant bacterial lysate
(S. pneumoniae Ply MT) with that inoculated with WT
bacterial lysate (S. pneumoniae WT). All mice inoculated
with S. pneumoniae Ply MT lysate survived (100% survival
by the end of the experiment, approximately 120 hr), sim-
ilarly to the vehicle-treated control mice, suggesting that
PLY is crucial in S. pneumoniae-induced lethality
Immunity
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induced severe lethality, similarly to S. pneumoniae WT
lysate (Figure 1B). Because the S. pneumoniae strain we
used in our studies, D39, is a virulent serotype 2 strain,
we sought to confirm whether another virulent strain also
induces lethality in mice in a similar way. As expected,
the virulent serotype 4 TIGR4, a S. pnuemoniae strain
that was used for sequencing the whole genome of S.
pneumoniae, also induced lethality similarly to strain D39
(see Figure S1 in the Supplemental Data available with
this article online), indicating that S. pneumoniae-induced
lethality may be also applied to other virulent strains of
S. pneumoniae.
PLY is well known to exert direct cytotoxic effects on the
alveolar-capillary barrier and thus induces ALI, one of the
important pathological processes causing death, espe-
cially during early phase of severe pneumococcal pneu-
monia (Cockeran et al., 2002; Grigoryev et al., 2004; Hol-
lingshed and Briles, 2001; Kadioglu and Andrew, 2004).
Indeed, pathological analysis of lung injury of S. pneumo-
niae WT- and PLY-inoculated but not S. pneumoniae Ply
MT-inoculated mice revealed massive alveolar hemor-
rhage 6 hr after inoculation (Figure 1C). Together, our
data suggest that S. pneumoniae PLY is crucial in ALI
and lethality in a mouse model of lethal S. pneumoniae in-
fections. Our findings from the mouse model are in line
with the typical pathological changes of pneumococcal
lobar pneumonia at the early stage in human patients
(Lagoa et al., 2005; Ware et al., 2005). Histologically, dur-
ing the initial stage of invasion, the affected human lung is
fully filled with red blood cells and fibrin but few polymor-
phonuclear neutrophils (PMNs). This stage, though sel-
dom recognized, was well described by Loeschcke
(1931) and is most found in patients who die within a short
time period after the onset of the diseases. Indeed, the
clinical and pathological evidence we directly obtained
from a patient who died within a short time period from
a pneumococcal lobar pneumonia was in full agreement
with our animal studies. Light microscopic examination re-
vealed that the alveolar spaces were diffusely filled with
red blood cells and a few PMNs (Figure S2). Thus, the find-
ings from our animal studies are highly relevant to human
diseases.
CYLD Deficiency Protects Mice against ALI
and Lethal S. pneumoniae Infections
To define the biological role of CYLD in vivo, we generated
Cyld-deficient mice (Cyld/mice) by replacing the exons
2 and 3 of the Cyld gene with a neomycin resistance-lacZ
cassette (Figure S3). Disruption of the Cyld gene is com-
patible with normal viability, development and fertility.
Genotyping was performed by PCR on tail-derived geno-
mic DNA, and germline transmission was confirmed by
Southern blot analysis. RT-PCR analysis confirmed the
absence of Cyld transcripts in homozygous mutant
mice, and immunoblot analysis of mouse embryonic fibro-
blast (MEF) using an antibody against CYLD showed
a deficiency of CYLD in Cyld/ mice. Interestingly,
Cyld-deficient mice exhibited no overt abnormalities andhave a normal lifespan. Based on our recent study show-
ing that CYLD is greatly induced by bacterial pathogens
(Jono et al., 2004; Yoshida et al., 2005), we hypothesized
that CYLD may play an important role in bacterial infec-
tions. Because CYLD expression is highly induced in
lung tissue, we initially sought to focus on elucidating
the role of CYLD in lethal lung infections induced by
S. pneumoniae PLY. We first determined whether CYLD
is induced by S. pneumoniae. CYLD expression at the
mRNA level was greatly upregulated by i.t. inoculation of
S. pneumoniae WT lysate or PLY but not S. pneumoniae
Ply MT lysate in lung tissues from WT mice (Figure 2A),
implying a potential role of CYLD during S. pneumoniae
infections.
To determine the role of CYLD in S. pneumoniae-
induced lethality,WT andCyld/micewere i.t. inoculated
with S. pneumoniae, and viability was then assessed. S.
pneumoniae WT lysate-inoculated Cyld/ mice started
to die within 48 hr after inoculation, and only 13% died
within 5 days (87% survival; Figure 2B). In contrast, WT
mice inoculated with S. pneumoniae WT lysate started to
die within a few hours after inoculation, and 91% of the
inoculated mice died within 48 hr (9% survival). Similar re-
sult was also observed in Cyld/ mice inoculated with
PLY (Figure 2C). Consistent with these findings, histo-
logical analysis showed that lungs from Cyld/ mice
exhibited almost no signs of ALI in comparison with
marked alveolar hemorrhage observed in lungs from WT
mice after S. pneumoniae WT lysate or PLY inoculation
(Figure 2D). Thus, our data demonstrate that CYLD defi-
ciency protects mice from S. pneumoniae PLY-induced
ALI and lethality. In addition to the pathological analysis,
we also examined the body temperature and performed
gravimetric analysis including extravascular lung water
and protein concentration. WT mice inoculated with
S. pneumoniaeWT lysate or PLY but not with S. pneumo-
niae Ply MT lysate showed significant decreases in body
temperature as compared with Cyld/ mice (Figure 2E).
Moreover, gravimetric analysis demonstrated that extra-
vascular lung water weight and total protein concentration
were significantly increased in lungsofWTmice inoculated
withS. pneumoniaeWT lysate or PLY but not withS. pneu-
moniae Ply MT lysate as compared with Cyld/ mice
(Figures 2F and 2G). Thus, these data suggest that Cyld
deficiency also protects mice from hypothermia and
microvascular leakage.
Next, we explored the possibility that the protective role
of Cyld deficiency may work in part by preventing translo-
cation of bacteria and bacterial dissemination by walling
off the infection in the lung, not just by preventing local
tissue injury in the lung. Bacterial counts were measured
in the lung and blood of WT and Cyld/ mice 24 hr after
i.t. inoculation of S. pneumoniaeWT D39 and S. pneumo-
niae PlyMT. Bacterial counts in the lungs ofWTmice inoc-
ulated with S. pneumoniae WT D39 were significantly
greater than those inoculated with S. pneumoniae Ply MT
(Figure S4A). Interestingly, the bacterial counts in the lungs
from WT mice inoculated with S. pneumoniae WT D39
strain were not statistically different from the counts ofImmunity 27, 349–360, August 2007 ª2007 Elsevier Inc. 351
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Regulation of S. pneumoniae Infections by CYLDFigure 2. Cyld Deficiency Protects Mice from ALI and Reduces Mortality in Lethal S. pneumoniae Infections
(A) CYLD mRNA expression from WT lung tissue was measured after incubation with S. pneumoniae WT, PLY, or Ply MT. *p < 0.05 compared with
CON; **p < 0.05 compared with WT. Data are the means ± SD (n = 3).
(B and C) Survival curves of WT and Cyld/ mice after i.t. inoculation of (B) S. pneumoniae WT or (C) PLY. *p < 0.0005 compared with CON in WT
mice; **p < 0.0005 compared with S. pneumoniae WT and PLY in WT mice.
(D) Representative pathological and histological analysis of the lungs of mice inoculated with S. pneumoniae WT and PLY in WT and Cyld/ mice
(Lower panel: H&E, 3100).
(E) Changes in body temperature in WT and Cyld/mice inoculated with S. pneumoniaeWT, Ply MT, and PLY. *p < 0.005; **p < 0.005; ***p < 0.05;
****p < 0.005 (n = 3 to 6).
(F) Total protein concentrations of BALF from the mice inoculated with S. pneumoniaeWT, Ply MT, and PLY in WT and Cyld/mice. *p < 0.05 com-
pared with CON in WTmice; **p < 0.05 compared with S. pneumoniaeWT or Ply MT in WTmice; ***p < 0.05 compared with S. pneumoniaeWT in WT
mice. Data are the means ± SD (n = 3 to 6).
(G) Lung water weight of WT and Cyld/ mice inoculated with S. pneumoniae WT, Ply MT, or PLY. *p < 0.00001 compared with CON in WT mice;
**p < 0.005 compared with S. pneumoniae WT and PLY in WT mice; ***p < 0.00001 compared with S. pneumoniae WT in WT mice. Data are the
means ± SD (n = 3 to 6).
Viability in (B) and (C) was assessed by using Kaplan-Meier survival analysis and compared by log-lank test (n = 10 to 44).the inoculated Cyld/ mice. In contrast, although bacte-
rial culture in the blood was positive in 6/10 (60%) in
the inoculated Cyld/ mice and positive in 7/10 (70%)
in the inoculated WT mice, circulating bacterial counts
in the blood from the inoculated Cyld/ mice were sig-
nificantly lower than those from the inoculated WT mice352 Immunity 27, 349–360, August 2007 ª2007 Elsevier Inc.(Figure S4B). These data indicate that the protective role
of CYLD deficiency may not only work by preventing ALI,
but also at least in part by attenuating translocation of bac-
teria andbacterial disseminationbywalling off the infection
in the lung. Collectively, our data suggest that CYLD in-
deed plays a crucial role in regulating ALI and bacterial
Immunity
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ing as a critical negative regulator for host survival.
CYLD Deficiency Protects against PLY-Induced
ALI and Death via PAI-1 Induction
Wenext sought to elucidate themolecular mechanisms by
which CYLD deficiency protects against ALI, one of the
major pathological processes contributing to S. pneumo-
niae-induced lethality during early course of pneumococ-
cal pneumonia (Bignell et al., 2000; Grigoryev et al., 2004;
Schwarz, 2001). In hemorrhagic infectious disease infec-
tion-induced fibrin deposition prevented the blood loss
in local tissue, suppressed anemia, and reduced hemor-
rhagic pathology in those diseases. Moreover, PAI-1 plays
an important role in preventing excessive hemorrhage and
deficiency of PAI-1 causes a bleeding diathesis in humans
(Happel et al., 2004; Lagoa et al., 2005; Ware et al., 2005),
and PAI-1 is not merely a marker of tissue injury but plays
a critical role in the recover from the local tissue damage.
Thus, we investigated if CYLD acts as a negative regulator
for PAI-1 expression and CYLD deficiency results in
elevated PAI-1 expression, which in turn leads to the di-
minished ALI and alveolar hemorrhage in lungs. To test
our hypothesis, we first assessed the expression of PAI-1
mRNA in MEF cells and lung tissues from WT and Cyld/
mice. The expression of PAI-1 at both mRNA and protein
levels is much higher in MEF and lung tissues from
Cyld/mice than that fromWTmice (Figure 3A). To deter-
mine whether higher PAI-1 expression in MEF cells from
Cyld/ mice is a developmental defect or simply results
from loss of the inhibitory function of CYLD on PAI-1
expression, we next evaluated the effects on PAI-1
mRNA expression of CYLD knockdown by using small
interfering RNA (siRNA)-CYLD and overexpression of WT
CYLD in MEF cells from WT and Cyld/ mice, respec-
tively. CYLD knockdown by using siRNA-CYLD increased
PAI-1 mRNA expression in WT MEF cells, whereas over-
expression of WT CYLD attenuated PAI-1 mRNA expres-
sion in Cyld/ MEF cells (Figure S5A). Similar results
were also observed when measuring PAI-1 promoter
activity. PAI-1 promoter activity was increased by siRNA-
CYLD in WT MEF, but attenuated by WT CYLD in Cyld/
MEF cells in a dose-dependent manner (Figure S5B). S.
pneumoniaeWT lysate and purified PLY, but not S. pneu-
moniae Ply MT lysate, induced PAI-1 expression in human
alveolar epithelial cell line A549, primary human small
airway bronchial epithelial SAEC and lungs of WT mice
(Figure S6). Moreover, induction of PAI-1 mRNA by S.
pneumoniae and PLY was observed in WT MEF cells and
mouse lung inoculated withS. pneumoniae 3 and 6 hr after
treatment, respectively, and the expression of PAI-1 were
much higher in Cyld/MEF and lung in both S. pneumo-
niae-treated and nontreated groups as compared with
that in WT MEF and mice lungs (Figures 3B and 3C). In
addition to the mRNA expression, PAI-1 protein expres-
sion was also measured in control and live S. pneumo-
niae-inoculated lung tissues from WT and Cyld/ mice
24 hr after inoculation. Highly enhanced immunoreactivity
signal for PAI-1 was detected in both control and infectedlungs from Cyld/ mice compared with those from WT
mice (Figure S7).
To determine if elevated PAI-1 expression is responsi-
ble for the diminished ALI and alveolar hemorrhage in
Cyld/ mice, we next evaluated the effect of neutraliza-
tion of PAI-1 in S. pneumoniae-induced ALI and lethality
by using a neutralizing monoclonal antibody against
PAI-1 (a-PAI-1). It should be noted that the neutralizing
antibody used in our study has been previously shown
to inhibit both mouse and rat PAI-1 activity (Declerck
et al., 1992), and its efficacy in neutralizing PAI-1 activity
has also been demonstrated both in vitro and in vivo (Berry
et al., 1998; Roca et al., 2003). Intraperitoneal (i.p.) pread-
ministration of a-PAI-1 enhanced ALI and alveolar hemor-
rhage in Cyld/ mice inoculated with S. pneumoniae
(Figure 3D). Consistent with these findings, S. pneumo-
niae-induced lethality was also markedly exacerbated by
i.p. inoculation of a-PAI-1 in Cyld/ mice (Figure 3E). To
further confirm if elevated PAI-1 expression is responsible
for the diminished ALI and lethality, we evaluated the
effect of exogenous PAI-1 on S. pneumoniae-induced
lethality as well as ALI in WT mice. i.t. inoculation with re-
combinant PAI-1 (rPAI-1) greatly reduced the mortality
rate in mice inoculated with S. pneumoniae or PLY
(Figures 3F and 3G). Consistent with these findings,
S. pneumoniae and PLY-induced alveolar hemorrhage
was also prevented in mice inoculated with rPAI-1 as
assessed by performing pathological and histological
analysis (Figure 3H).
To further confirm whether PAI-1 deficiency indeed po-
tentiates ALI and reduces survival rate,WTandSerpine1/
(encoding PAI-1) mice were i.t. inoculated with live
S. pneumoniae, S. pneumoniae WT lysate, and PLY and
viability was then assessed for 5 days after inoculation.
Serpine1/ mice were significantly more susceptible to
S. pneumoniae inoculation than were WT mice (Figures
4A–4C). Serpine1/mice inoculated with live S. pneumo-
niae, S. pneumoniae WT lysate, and PLY started to die at
earlier time points and all died within 5 days after inocula-
tion as compared with WT mice. Consistent with these
findings, S. pneumoniae- and PLY-induced ALI and alve-
olar hemorrhage was also enhanced in Serpine1/ mice
in comparison with WT mice (Figure 4D). Our findings
are in contrast to those of a previous report (Rijneveld
et al., 2003), which showed no substantial influence of
PAI-1 deficiency on the outcome of murine pneumococcal
pneumonia. The differences in bacteria strain (D39 versus
ATCC 6303), inoculation route (i.t. versus i.n.), or inocula-
tion dosage (53 107 CFU versus 23 105 CFU) used in the
two studies may contribute to the discrepancy. To exper-
imentally address these differences, S. pneumoniae strain
D39 was intranassally (i.n.) inoculated in both WT and
Serpine1/ mice to determine whether different inocula-
tion route would affect on the protective role of the PAI-1
in S. pneumoniae-induced lethality. Serpine1/ mice
showed higher mortality than WT mice when mice were
i.n. inoculated with 5 3 107 CFU of strain D39
(Figure S8A). Because S. pneumoniae ATCC 6303, which
was used in previous report (Rijneveld et al., 2003), wasImmunity 27, 349–360, August 2007 ª2007 Elsevier Inc. 353
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Regulation of S. pneumoniae Infections by CYLDFigure 3. Cyld Deficiency Protects against Pneumolysin-Induced ALI and Death via Enhancement of PAI-1 Expression in Lung
(A) PAI-1 mRNA (upper panels) and protein (lower panels) expression from MEFs and lung tissues of WT and Cyld/mice were measured. *p < 0.05
compared with WT. Data are the means ± SD (n = 3).
(B and C) PAI-1 mRNA expression from (B) MEFs and (C) lung tissues of WT and Cyld/mice was measured after incubation with S. pneumoniae or
PLY. *p < 0.005 compared with CON in WT, **p < 0.0005 compared with S. pneumoniae or PLY in WT. Data are the means ± SD (n = 4).
(D) Representative H&E-stained lung sections from Cyld/mice after inoculation with S. pneumoniae with or without i.p. a-PAI-1 preadministration
(25 mg/mouse) 2 hr before S. pneumoniae inoculation (H&E stain, 3200).
(E) Survival curves of Cyld/mice after i.t. inoculation of S. pneumoniae lysate with or without preadministration of a-PAI-1 (50 mg/mouse) or control
IgG 2 hr before S. pneumoniae inoculation. *p < 0.005 compared with control IgG.
(F and G) Survival curves of WT mice after i.t. inoculation of (F) S. pneumoniae lysate or (G) PLY with or without preadministration of rPAI-1 (12.5 mg/
mouse) or saline 1 day before S. pneumoniae or PLY inoculation. *p < 0.0005 compared with CON; **p < 0.0005 compared with S. pneumoniae or PLY
inoculation without rPAI-1 preadministration.
(H) Representative pathological and histological analysis of the lungs of mice inoculated with S. pneumoniae or PLY with or without preadministration
of rPAI-1 in WT mice (Lower panel: H&E, 3100).
Viability in (E)–(G) was assessed by using Kaplan-Meier survival analysis and compared by log-lank test (n = 10 to 44).known as a strain possessed higher lethality to the mice
compared with other strains, next we examined lethality
of two different strains (D39 versus ATCC 6303) in WT354 Immunity 27, 349–360, August 2007 ª2007 Elsevier Inc.mice. All the mice inoculated with strain ATCC 6303 died
within 3 days, but only 40% of the strain D39-inoculated
mice died by 5 days after inoculation, when animals
Immunity
Regulation of S. pneumoniae Infections by CYLDFigure 4. Serpine1/ Mice Are Hypersusceptible to Severe S. pneumoniae Infection
(A–C) Survival curves of WT and Serpine1/ mice after i.t. inoculation of (A) live S. pneumoniae, (B) S. pneumoniae lysate, and (C) PLY. *p < 0.001
compared with CON in WT mice; **p < 0.05 compared with live S. pneumoniae, S. pneumoniae lysate, or PLY in WT mice.
(D) Representative H&E-stained lung sections fromWT and Serpine1/mice after inoculation with S. pneumoniae lysate and PLY (H&E stain,3200).
Viability in (A)–(C) was assessed by using Kaplan-Meier survival analysis and compared by log-lank test (n = 10 to 44).were i.n. inoculated with 5 3 107 CFU of the bacteria
(Figure S8B). Moreover, WT mice inoculated with 2 3 105
CFU of strain ATCC 6303 mice started die 3 days after in-
oculation and showed around 55%of the survival rate, but
none of WT mice inoculated with 2 3 105 CFU of strain
D39 died by the end of the experiment. Because two bac-
teria strains possessed different lethality in mice, we next
thought higher toxicity of strain ATCC 6303 would affect
on the protective role of PAI-1 in ALI and death. Therefore,
we examined the protective role of the PAI-1 against strain
ATCC 6303 in WT and Serpine1/ mice. Consistent with
our findings with strain D39, strain ATCC 6303 inoculated
Serpine1/ mice showed higher mortality than WT mice
(10% survival versus 45% survival, respectively), when
animals were i.n. inoculated with 23 105 CFU of the bac-
teria (Figure S8C). Taken together, our data suggest that
PAI-1 plays a critical protective role in lethal pneumococ-
cal infections.
S. pneumoniae PLY Induces PAI-1 Expression via
MKK3-p38 MAPK Signaling Pathway
We next sought to determine how PAI-1 is induced in
pneumococcal pneumonia. On the basis that PAI-1 is reg-
ulated by p38 mitogen-activated protein kinase (MAPK;
Kietzmann et al., 2003; Norata et al., 2004), it is logical
to investigate whether MAPK kinase 3 (MKK3)-p38
MAPK signaling is required for S. pneumoniae-induced
PAI-1 expression. We initially examined if S. pneumoniae
induces activation of MKK3 and p38. S. pneumoniae WT
and purified PLY but not S. pneumoniae Ply MT induced
potent phosphorylation of both p38 and MKK3 in A549
cells (Figure 5A). To determine whether MKK3-p38
signaling pathway is involved in S. pneumoniae-inducedPAI-1 expression, we assessed the effects of perturbing
MKK3-p38 signaling on PAI-1 expression using various
approaches. TreatmentwithSB203580, a specific inhibitor
for p38, and overexpressing dominant-negative mutant
(DN) forms of p38a, p38b, and MKK3 greatly reduced
S. pneumoniae-induced PAI-1 expression in A549 cells
(Figure 5B). In addition, SB203580 also inhibited PAI-1
induction by S. pneumoniae WT and PLY in BEAS-2B,
SAEC, and NHBE cells (data not shown). Next, we con-
firmed the requirement of MKK3 in PAI-1 expression using
Mkk3-deficient mice (Lu et al., 1999) by showing that
S. pneumoniae-induced PAI-1 expression was greatly
reduced in Map2k3/ (encoding Mkk3) mouse lung as
compared with that in WT mouse lung (Figure 5C). Thus,
our data suggest that MKK3-p38 signaling is required for
S. pneumoniae-induced PAI-1 expression in lung.
To determine whether Mkk3 deficiency also potentiates
ALI and reduces survival rate, WT and Map2k3/ mice
were first i.t. inoculated with live S. pneumoniae, S. pneu-
moniaeWT lysate, Ply MT lysate, or PLY, and viability was
then assessed for 5 days after inoculation. Approximately
80% of Map2k3/ mice inoculated with live S. pneumo-
niae died within 48 hr and 100% died within 72 hr
(Figure 5D). In contrast, approximately 25% of inoculated
WTmice diedwithin 48 hr and 66%diedwithin 72 hr. Inter-
estingly, PLY-inoculated Map2k3/ mice started to die
within a few hours after inoculation and 100% of the inoc-
ulatedmicediedwithin 6hr (Figure 5E). Similar resultswere
also observed inMap2k3/mice inoculatedwithS. pneu-
moniae WT lysate but not with S. pneumoniae Ply MT
lysate (Figure 5F). Consistent with these findings, histolo-
gical analysis showed that lungs from Map2k3/ mice
exhibited more massive alveolar hemorrhage comparedImmunity 27, 349–360, August 2007 ª2007 Elsevier Inc. 355
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Regulation of S. pneumoniae Infections by CYLDFigure 5. S. pneumoniae Pneumolysin Induces PAI-1 Expression via MKK3-p38 MAPK Signaling Pathway
(A) S. pneumoniae WT and PLY but not S. pneumoniae Ply MT induced phosphorylation of p38 and MKK3 in A549 cells.
(B) S. pneumoniae-induced PAI-1 mRNA expression was inhibited by using SB203580 and expressing dominant-negative mutant form of p38a and
p38b and MKK3 in A549 cells. Data are the means ± SD (n = 3).
(C) PAI-1 mRNA expression was measured from lung tissues fromWT andMap2k3/mice after incubation with S. pneumoniae. *p < 0.05 compared
with CON; **p < 0.0001 compared with S. pneumoniae in WT. Data are the means ± SD (n = 4).
(D–F) Survival curves of WT andMap2k3/ mice after inoculation with (D) live S. pneumoniae, (E) PLY, or (F) S. pneumoniaeWT and Ply MT lysate.
*p < 0.0005 compared with live S. pneumoniae in WT mice, **p < 0.05 compared with PLY in WT mice, ***p < 0.05 compared with S. pneumoniae
WT lysate in WT mice, ****p < 0.0005 compared with S. pneumoniae WT in Map2k3/ mice.
(G) Representative H&E-stained lung sections from WT and Map2k3/ mice after inoculation with S. pneumoniae lysate or PLY (H&E stain, 3100).
Viability in (D)–(F) was assessed by using Kaplan-Meier survival analysis and compared by log-lank test (n = 10 to 44).to lungs fromWTmice after S. pneumoniae and PLY inoc-
ulation (Figure 5G). Together, these data suggest that
MKK3-p38 signaling is indeed required for S. pneumo-
niae-induced PAI-1 expression in vitro and in vivo.
CYLD Negatively Regulates PAI-1 Expression via
Inhibition of S. pneumoniae-Induced MKK3-p38
Pathway
Next, we sought to determine if CYLD deficiency leads to
enhancement of PAI-1 expression and protects against
lethality via negative crosstalk with p38MAPK.We first de-
termine whether MKK3-p38 activity is higher in Cyld/
cells. Activation of both MKK3 and p38 by S. pneumoniae
appears to be more potent inCyld/MEF than that in WT
MEF (Figure 6A). Similar resultwas also observed inCyld/
cells treated with PLY. Then we assessed the effect on
PAI-1 expression of perturbing p38 signaling in Cyld/
cells treated with or without S. pneumoniae and PLY. Pre-356 Immunity 27, 349–360, August 2007 ª2007 Elsevier Inc.treatment with SB203580 reduced PAI-1 expression in
Cyld/ cells treated with S. pneumoniae (Figure 6B) or
PLY (Figure 6C). Our data thus suggest that CYLD acts
as a negative regulator for S. pneumoniae-induced PAI-1
expression via negative crosstalk with the MKK3-p38
MAPK signaling pathway. To further determine if CYLD
deficiency indeed protects mice from S. pneumoniae-in-
duced lethality via enhancement of p38 MAPK activity,
we evaluated the effect of perturbing p38 signaling on
the survival rate of Cyld/ mice inoculated with S. pneu-
moniae. SB203580-pretreated Cyld/mice started to die
12 hr after inoculation and approximately 80% of the
inoculatedmicediedwithin 48hr (20%survival; Figure 6D).
In contrast, SB203580-nonpretreated Cyld/ mice inoc-
ulated with S. pneumoniae started to die 48 hr after inoc-
ulation and only 13%of the inoculatedmice died by end of
the experiment (87% survival). Taken together, our data
indicate that CYLD plays a crucial role in negatively
Immunity
Regulation of S. pneumoniae Infections by CYLDFigure 6. CYLD Acts as a Negative Reg-
ulator for PAI-1 Expression via Negative
Crosstalk with MKK3-p38 MAPK
Signaling Pathway
(A) Kinetics of S. pneumoniae- and PLY-in-
duced MKK3 and p38 phosphorylation in
MEF from WT and Cyld/ mice.
(B and C) PAI-1 mRNA expression was mea-
sured fromMEFs of WT and Cyld/ after incu-
bation with (B) S. pneumoniae or (C) PLY pre-
treated with or without SB203580 (SB). *p <
0.05 compared with S. pneumoniae or PLY in
WTMEF; **p < 0.05 comparedwithS. pneumo-
niae or PLY without SB. Data are the means ±
SD (n = 4).
(D) Survival curves of Cyld/ mice after S.
pneumoniae inoculation with vehicle or SB
(10 mg/kg) pretreatment 2 hr before S. pneu-
moniae inoculation. *p < 0.0005 compared
with S. pneumoniae inoculation without SB
pretreatment. Viability in (D) was assessed by
using Kaplan-Meier survival analysis and com-
pared by log-lank test (n = 10 to 44).regulating MKK3-p38 MAPK-dependent expression of
PAI-1, thus potentiating ALI and S. pneumoniae-induced
lethality.
TLR4-MyD88 Signaling Is Required for
S. pneumoniae PLY-Induced PAI-1 Expression
Because TLR2 and 4 and their immediate downstream
signaling transducer MyD88 play an important role in the
pathogenesis of S. pneumoniae infections and TLR4 was
shown to be the receptor for PLY (Srivastava et al., 2005),
we determined if TLR2 or TLR4 is also involved in S. pneu-
moniae PLY-induced PAI-1 expression. Overexpressing
a DN of TLR4 and MyD88 but not TLR2 inhibited both
S. pneumoniae- and PLY-induced PAI-1 expression in
A549 cells (Figure S9A and data not shown), suggesting
that TLR4-MyD88 signaling is required for PLY-induced
PAI-1 expression. The requirement for TLR4 signaling in
PLY-induced PAI-1 mRNA expression was further con-
firmed in vivo by using TLR4-deficient mice. PLY-induced
PAI-1 expression was much lower in the lungs of Tlr4/
mice than that in WT mice (Figure S9B). To further deter-
mine if exogenous rPAI-1 also reduces mortality rate in
Tlr4/ mice, Tlr4/ mice were i.t. inoculated with PLY
with or without rPAI-1 pre-administration and viability
was assessed. rPAI-1 inoculation fully protected mice
from lethal challenge (Figure S9C). Together, our data
suggest that TLR4-MyD88 signaling is indeed required
for PLY-induced PAI-1 expression in vitro and in vivo.
DISCUSSION
We have shown here that tumor suppressor CYLD defi-
ciency protects mice from S. pneumoniae PLY-induced
ALI, bacterial translocation and lethality, thus acting as
a negative regulator for host survival in lethal S. pneumo-
niae infections. Our data demonstrate that CYLD, highly
induced by S. pneumoniae, negatively regulates MKK3-p38 MAPK-dependent PAI-1 expression in lung, which in
turn leads to enhanced ALI, severe hemorrhage, and
increased mortality. Of particular interest in the current
study is that CYLD acts as a negative regulator for host de-
fense against lethal bacterial infections. Despite the
experimental evidence for the negative regulation of p38
by CYLD in vitro, the biological consequence of the nega-
tive crosstalk between CYLD and p38 MAPK remains
unknown. Thus, the present study showed that inhibition
of p38 by CYLD leads to reduced expression of PAI-1
expression in lung and contributes substantially to ALI
and increasedmortality rate in lethal S. pneumoniae infec-
tions. Given the complex regulatory mechanisms of ALI
during bacterial infections (Chapman et al., 1990; Olman
et al., 1995; Prabhakaran et al., 2003; Suffrendini et al.,
1989), our data do not preclude the other molecular mech-
anism involved in this complicated pathological process.
Another major interesting finding in this study is the
experimental evidence for the protective role of PAI-1 in
reducing early mortality rate in lethal pneumococcal pneu-
monia. PAI-1 is a very complex protein that is tightly reg-
ulated at transcriptional level, and its role in bacterial in-
fections still remains largely unknown. We found that the
endogenous PAI-1 was upregulated at the levels of both
mRNA and protein in the lungs of WT mice inoculated
with S. pneumoniae. We further observed enhanced lung
injury and alveolar hemorrhage as well as a reduced sur-
vival rate in Serpine1/ mice, thereby demonstrating
the protective role of endogenous PAI-1 during pneumo-
coccal pneumonia. Furthermore, we showed that i.t. ad-
ministration of exogenous rPAI-1 prevented tissue injury
and reduced mortality rate. Together our data provide di-
rect evidence for the protective role of PAI-1 during severe
pneumococcal pneumonia in vivo. Our finding is in line
with a recent report showing that Serpine1/ mice are
more susceptible to Gram-negative bacterial infection
(Renckens et al., 2006). In addition to its role in reducingImmunity 27, 349–360, August 2007 ª2007 Elsevier Inc. 357
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Regulation of S. pneumoniae Infections by CYLDlung injury, PAI-1 was also shown to prevent bacterial
translocation from lung into blood circulation (data not
shown). Taken together, it is evident that PAI-1 plays a crit-
ical role in reducing mortality rate during early stage of
severe pneumococcal pneumonia not only by preventing
tissue damage but also reducing bacterial translocation
into systemic circulation. Administration of exogenous
PAI-1 may help to reduce high early mortality in lethal
pneumococcal pneumonia.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies
SB203580, Wedelolactone, mouse rPAI-1 and a-PAI-1 neutralizing an-
tibody (MA-33H1F7) were purchased from Calbiochem. The following
antibodies were purchased from Cell Signaling Technology: phospho-
MKK3/6, phospho-p38 MAPK, MKK3, p38 MPAK, HRP-conjugated
mouse IgG, and HRP-conjugated rabbit; b-actin antibody was from
Sigma; CYLD polyclonal antibody was described previously (Jono
et al., 2004).
Bacteria, Bacterial Lysate, and PLY
Clinical isolates of S. pneumoniaeWT strain D39 (serotype 2) and D39
isogenic mutant strain deficient in pneumolysin gene (Ply MT) were
used in this experiment. To determine the virulence factor responsible
for causing ALI and lethality as well as for PAI-1 induction, live S. pneu-
moniae (5 3 107 CFU), S. pneumoniae lysate (equivalent to 5 3 107
CFU), and 200 ng of purified native PLY were used in the experiments.
Native PLY was described previously (Srivastava et al., 2005).
Cells, Plasmids, and Transfections
Human alveolar epithelial A549 cells were maintained as described
(Wang et al., 2002). WT and Cyld/ MEF cells were obtained from
E13 embryos and maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS). All cells
were cultured in a humidified atmosphere of 5% saturated CO2 atmo-
sphere at 37C. The expression plasmids MKK3 DN, p38a DN, and
p38b DN were described previously (Imasato et al., 2002). Cells were
cultured on 12-well plates and transfected with various expression
plasmids as indicated in the figure legend. All transient transfections
were carried out using a TransIT-LT1 reagent (Mirus) following the
manufacturer’s instructions.
Mice
Cyld/ mice were generated by homologous recombination as fol-
lows: the targeting construct was designed to disrupt the exons 2
and 3 with an IRES-LacZ/MC1-Neo cassette. The targeting plasmid
was linearized and transfected into embryonic stem cells of a 129/S.
Homologously recombined embryonic stem cells were injected into
blastocysts that were subsequently transferred to foster mothers, to
generate chimeric progeny. Generated chimeric progeny were back-
crossed to C57BL/6J and germline transmission was confirmed by
PCRwith tail DNA. Homozygous knockout ofCyld genewas confirmed
by mRNA detection by RT-PCR and CYLD protein detection by Immu-
noblot analysis in MEF cells and lung tissues. Map2k3/ mice have
been described previously (Lu et al., 1999) and Serpine-1/ mice
were purchased from the Jackson laboratory. Age-matched back-
ground C57BL/6J mice were used as wild-type controls. All animal
experiments were approved by the Institutional Animal Care and Use
Committee at University of Rochester.
Animal Experiments
ForS.pneumoniae-induced lethal infections inWT,Cyld/,Map2k3/,
and Serpine-1/ mice, anaesthetized mice were i.t. inoculated with
live S. pneumoniae, S. pneumoniae WT or Ply MT lysate or PLY at
a concentration of 53107CFUpermouse for live bacteria andbacterial358 Immunity 27, 349–360, August 2007 ª2007 Elsevier Inc.lysate and 200 ng/mouse for PLY in all experiments unless otherwise
indicated in figure legends, and saline was inoculated as control. The
mice were monitored for lethality every 2 hr for 12 hr and every 12 hr
for 5 days thereafter. To assess the effect of perturbing p38MAPK sig-
naling on S. pneumoniae-induced lethality in Cyld/ mice, Cyld/
mice were pretreated with the p38 inhibitor SB203580 (10 mg/kg, i.p.
in Cyld/ mice) 2 hr before S. pneumoniae inoculation, and mice
were then i.t. inoculated with S. pneumoniae. To determine the effect
of administration of exogenous PAI-1 on S. pneumoniae-induced
lethality, WT mice were i.t. administered with mouse rPAI-1 (12.5 mg/
mouse) or saline as control, followed by S. pneumoniae and PLY inoc-
ulation 1 day after rPAI-1 administration. For PAI-1 neutralization in
Cyld/ mice, Cyld/ mice were i.p. inoculated with a-PAI-1 mAb
(25mg/mouse for histological analysis and 50mg/mouse for the lethality)
2 hr before S. pneumoniae inoculation, and control mouse IgG was
used as control. For S. pneumoniae- and PLY-induced MAPK phos-
phorylation, PAI-1 and CYLD mRNA and protein expression, and ALI,
anaesthetized mice were i.t. inoculated with S. pneumoniae or PLY
with or without SB203580, rPAI-1, or a-PAI-1 mAb, and mice were
then sacrificed at 6 hr after inoculation of S. pneumoniae unless other-
wise indicated in figure legend. Lung tissueswere then subjected tohis-
tological analysis and total mRNA and protein extraction.
Real-Time Quantitative RT-PCR
Quantitative analysis of mRNA expression was performed using the
ABI PRISM 7500 sequence detection system (Applied Biosystems)
according to the manufacturer’s instructions as described previously
(Yoshida et al., 2005). The primers for CYLD and PAI-1 were described
previously (Jono et al., 2003).
Immunoblot Analysis
Immunoblot analysis was performed as described previously (Yoshida
et al., 2005). Cell and whole-lung lysates were prepared and incubated
with phospho-MKK3/6, phospho-p38 MAPK, MKK3, p38 MPAK,
b-actin, CYLD, or PAI-1 antibody. Protein bands were visualized using
secondary HRP-conjugated rabbit or mouse IgG antibody and the ECL
detection system (Amersham Biosciences), detected using IS400R
(Kodak), and quantitative protein expression was analyzed by using
Kodak MI Alias (Kodak).
Histology
For histological analysis, dissected lungswere fixedwith 10%buffered
neutral formalin overnight followed by routine processing, embedded
in paraffin, and sectioned at 4 mm thickness. Sections were then
stained with H&E stain to visualize ALI. H&E-stained lung tissue slides
were evaluated by light microscopy using Axiovert 40 CFL (Carl Zeiss),
and images were recorded with an AxioCam MRC (Carl Zeiss).
Statistical Analysis
Differences in survival between WT and Cyld/, Map2k3/, and
Serpine-1/ mice after S. pneumoniae, S. pneumoniae lysate and
PLY inoculation with or without SB203580, rPAI-1, or a-PAI-1 mAb
were determined by Kaplan-Meier analysis using SPSS 14.0 software
(SPSS Inc.). All in vivo survival rate data were evaluated by log-lank test
and statistical significance was accepted at a value of p < 0.05. All
other in vivo and in vitro data were evaluated by Student’s t test and
statistical significance was accepted at a value of p < 0.05.
Supplemental Data
Nine figures are available at http://www.immunity.com/cgi/content/
full/27/2/349/DC1/.
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